News

If you’re bothered by allergies every spring, you may pop a Benadryl or Claritin most mornings to make the days tolerable.
Eyestem Research, a Bangalore-based cell therapy company, is pleased to announce significant vision improvement in Phase 1 trials of its investigational drug, Eyecyte-RPEtm, in patients with ...
Marin Independent Journal on MSN8h
Marin allergy season in full swing
Without rain to tamp it down, pollen has gone airborne, signaling that spring allergy season has arrived in Marin. "The grass pollen already started up a couple of weeks ago, and the juniper pollen a ...
Allergies, whether spring sneezes due to pollen or trouble breathing triggered by a certain food, are caused by a combination of someone's genes and the environment they live in.
The more things two people share, the higher their chances of being allergic to the same things. Twins are more likely to share allergies because of everything they have in common, but the story doesn ...
Learn more about whether Ligand Pharmaceuticals Incorporated or Viatris Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.
Forget the temperature – for hayfever sufferers the pollen count is also a key metric that can turn what otherwise looks like a beautiful day for riding into a nightmare no-go. Hayfever season lasts ...
April and I got off the bus and joined a knot of smokers on Sophia Street outside the Recovery Club. There were a couple nods of recognition. I didn’t know if people recognized me personally or just ...
New studies in rats suggest the drug reserpine, approved in 1955 for high blood pressure, might treat the blinding disease ...
The US Food and Drug Administration (FDA) has approved the sale of Bruno Vision Care’s Deseyne contact lenses, which incorporate FusionTechnology, in the American market. The lenses integrate the ...
Only one reliable treatment for the sexually transmitted infection still exists, because the bacteria that cause it have ...
Revenue Surges 234%, Expenses Down 21%, EPS Improves 77%, with Over $18.3 Million Licensing Incomes Available SILICON VALLEY, CA - April 15, 2025 (NEWMEDIAWIRE) - ABVC BioPharma, Inc. (NASDAQ: ABVC), ...